Metabolism of GM1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses,sialidoses, and sphingolipid activator protein (SAP,saposin) 1 and prosaposin deficient disorders

Summary Cultured skin fibroblasts from controls and patients with lysosomal storage diseases were loaded with G_M1 ganglioside that had been labelled with tritium in its ceramide moiety. After a 65-h or 240-h incubation, a large percentage of this ganglioside remained undegraded in G_M1 gangliosidoses, whereas in the other storage diseases studied, one of its metabolites accumulated by 2–4 fold relative to controls. Labelled G_M2 ganglioside accumulated in 4 variants of G_M2 gangliosidosis, whereas labelled G_M3 ganglioside accumulated in sialidosis, galactosialidoses and sphingolipid activator protein 1 (SAP-1, saposin B) and prosaposin (saposin A, B, C an D) deficient lipidoses. The reduced degradation of G_M3 ganglioside in the SAP-1 and prosaposin deficiencies was attributed to the deficient function of SAP-1. The prosaposin deficient cells also showed a reduced re-utilization of radioactive metabolites from G_M1 ganglioside (i.e. sphingosine and fatty acid) for phospholipid biosynthesis compared with fibroblasts from the SAP-1 deficient patient or normal controls. This anomaly was ascribed to the previously shown defect in ceramide degradation in prosaposin deficiency.